Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children

NEXT STORY
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
PREV STORY
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

NEW YORK and CLEVELAND, May 30, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), ...

author_avatar
NASDAQ Market News

Verrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of Schedule

Innovate trial results reaffirm Phase 3 protocol design No serious adverse events (SAEs) reported ...

author_avatar
NASDAQ Market News

Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02

Extends IP protection of TG02 in the US until 09.12.2034Oslo, 3 October 2017: Targovax ...

author_avatar
NASDAQ Market News